Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Blincyto (blinatumomab)
pCPA File Number:
20972
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute Lymphoblastic Leukemia
Sponsor/Manufacturer:
Amgen Canada Inc.
CADTH Project Number:
pCODR 10097
pCPA Engagement Letter Issued:
2017-12-29
Negotiation Process Concluded:
2019-01-15